12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
In a legal challenge to a corporate transaction, the applicable standard of review is often outcome ...
Read More >
In August 2013, Arkansas enacted a statute intended to regulate employers’ ability to access social...
Read More >
In most industries, it is common for employers to implement no-fault attendance policies to discipli...
Read More >
Businesses may receive a bit of breathing room as a result of two amendments to the California Consu...
Read More >
In the context of the practice of medicine, we are all very familiar with the Latin phrase primum es...
Read More >
In “La La Land,” Damien Chazelle’s Oscar winning film, the audience thinks it has a formulaic Hol...
Read More >